401 related articles for article (PubMed ID: 31306553)
1. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
[TBL] [Abstract][Full Text] [Related]
2. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
Smolle MA; Calin HN; Pichler M; Calin GA
FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Skafi N; Fayyad-Kazan M; Badran B
Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
[TBL] [Abstract][Full Text] [Related]
4. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Kalantari Khandani N; Ghahremanloo A; Hashemy SI
J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
[TBL] [Abstract][Full Text] [Related]
5. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
Zhulai G; Oleinik E
Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
[TBL] [Abstract][Full Text] [Related]
7. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Liu D; Wang S; Bindeman W
J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Checkpoint Inhibition.
Weber JS
Am Soc Clin Oncol Educ Book; 2017; 37():205-209. PubMed ID: 28561695
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
12. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
13. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
15. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
16. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
